APA (7th ed.) Citation

Radhika, P., Akashi, A., Tanith, W., Salina, L., Adam, J., & Alfred, S. (2025). 112 Real-World Outcomes in Patients treated with First-line Anti-PD(L)-1 Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer - A Single Tertiary Centre Experience. Lung Cancer (01695002), 200, N.PAG. https://doi.org/10.1016/j.lungcan.2025.108222

Chicago Style (17th ed.) Citation

Radhika, Patel, Alam Akashi, Westerman Tanith, Lalwani Salina, Januszewski Adam, and So Alfred. "112 Real-World Outcomes in Patients Treated with First-line Anti-PD(L)-1 Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer - A Single Tertiary Centre Experience." Lung Cancer (01695002) 200 (2025): N.PAG. https://doi.org/10.1016/j.lungcan.2025.108222.

MLA (9th ed.) Citation

Radhika, Patel, et al. "112 Real-World Outcomes in Patients Treated with First-line Anti-PD(L)-1 Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer - A Single Tertiary Centre Experience." Lung Cancer (01695002), vol. 200, 2025, p. N.PAG, https://doi.org/10.1016/j.lungcan.2025.108222.